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Summary Commercially available immunoradiometric assays were used for pS2 and total cathepsin D
determination in the cytosol fraction obtained from 266 primary breast cancers. We show that pS2 and
cathepsin D values were significantly associated (Spearman's rank correlation: P<0.0001) in tumours from
lymph node-positive patients (N+), while such association did not reach significance in tumours taken from
patients with negative lymph nodes (N-). Moreover, cathepsin D concentrations in pS2-rich tumours (pS2
above the median value, 5 ng mg-' protein) were significantly higher (Mann-Whitney-Wilcoxon's rank-sum
test: P = 0.00001) than those obtained in the samples expressing less than 5 ng of pS2 per mg of protein. pS2
was also correlated to both the oestrogen receptor (ER) (Spearman's rank correlation: P<0.0001) and the
progesterone receptor (PR) (Spearman's rank correlation: P = 0.022). No significant differences in the ex-
pression of pS2 and cathepsin D taken from N+ and N- patients were found. Furthermore, no significant
differences in pS2 and cathepsin D expression were obtained by stratifying tumours on the basis of their size
(T). pS2 and cathepsin D values obtained in ER-positive/PR-positive tumours did not significantly differ from
the values obtained in ER-positive/PR-negative and in ER-negative/PR-positive tumours. We conclude that
pS2 could have a role in cathepsin D expression, and that it can be used in the assessment of a functioning
oestrogen response machinery in those tumours that express only ER.
The assay of oestrogen receptor (ER) has become a routine
procedure in the clinical evaluation of breast cancer (Byar et
al., 1979; Allegra et al., 1980). Along with ER, the presence
of progesterone receptor (PR) (Clark et al., 1983; Alexieva-
Figusch et al., 1988) and pS2 protein (Rio et al., 1987; Henry
et al., 1991; Predine et al., 1992) is considered to reflect a
functional mechanism by which the tumour cells are able to
respond to oestrogen stimulation. Like PR and pS2, cathep-
sin D synthesis is also controlled by oestrogen in the human
breast cancer cell line MCF-7 (Westley & Rochefort, 1980;
Rochefort et al., 1987). However, both cathepsin D and pS2
are also released as constitutive products in hormone-
independent systems. Thus, pS2 has been immunohisto-
chemically detected in the stomach mucosa of healthy
subjects (Rio et al., 1988a), while cathepsin D has been found
in ER-negative cell lines (Westley & Rochefort, 1980).
Clinically, pS2 can be considered an additional marker of
hormone sensitivity, while cathepsin D in some studies
appeared to have powerful predictive values (Spyratos et al.,
1989; Thorpe et al., 1989; Tandon et al., 1990; Kute et al.,
1992), although in others it did not (Henry et al., 1990;
Janicke et al., 1993). Similarly, many studies have suggested
that cathepsin D may have a role in tumour progression and
invasiveness (Rochefort, 1992), but others have shown
strongly contrasting results (Johnson et al., 1993; Ravdin,
1993). The physiological role of pS2 is still unclear. Never-
theless, pS2 shows a high degree of homology with the two
insulin-like growth factors, IGFI and IGFII (Rio et al.,
1988b); interestingly, cathepsin D can bind to the IGFII
receptor, modulating its growth stimulatory action (Mathieu
et al., 1990).
The study reported here was performed to evaluate rela-
tionships between pS2 and several prognostic factors, namely
ER, PR, cathepsin D, axillary node metastasis and tumour
size, in a population of 266 women living in the Apulia area
of Italy.
Materials and methods
Patient data
A consecutive series of 266 primary breast carcinomas were
collected at surgery from November 1991 to December 1992
and analysed by two different Italian Laboratories (V. Fazzi's
Hospital of Lecce, n = 126 specimens; Oncology Institute of
Bari, n = 140 specimens) that register approximately 90% of
all primary breast cancer patients living in the District of
Apulia. The two laboratories cooperating in this study par-
ticipated in the European Program of Quality Control for
Hormone Receptor Assay.
All patients were females between 32 and 87 years of age
(mean and median age were 56). None had received
preoperative tamoxifen therapy. One hundred and forty-four
of the 266 patients (54%) were post-menopausal. According
to the TNM classification, 104 (39.1%) were classified as TI,
113 (42.5%) as T2, 28 (10.5%) as T3 and 21 (7.9%) as T4
tumours. Lymph node metastasis as determined by histo-
logical examination was noted in 117 cases (44%).
Tissue handling
Human breast tumour tissue was obtained at operation. The
tissue was placed on ice for periods of no more than
10-15min, until tumour tissue could be histologically
identified, excised and snap frozen in liquid nitrogen.
Tumour tissue was homogenised, using an Ultra-Turrax
homogeniser, in glycerol phosphate buffer of low ionic
strength [10% glycerol (v/v), 10mM dipotassium hydrogen
phosphate/potassium dihydrogen phosphate, 1.5 mm EDTA,
10 mm magnesium chloride], containing 1 yg ml-' of each of
the protease inhibitors soybean trypsin inhibitor, leupeptin
and aprotinin, and 1 mM phenylmethylsulphonyl fluoride (all
from Sigma, Poole, Dorset, UK). The homogenate was
centrifuged for 15 min at 900 g at 4'C. The supernatant was
centrifuged again for 60min at 100,000 g and the resulting
supernatant (termed 'cytosol') was used for pS2, cathepsin D,
ER and PR determinations.
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Immunoradiometric assay ofpS2 and cathepsin D
pS2 and total cathepsin D assay were performed by solid-
phase two-site immunoradiometric assays according to the
instructions provided with the CIS Biointernational Kits
(Gif-Sur-Yvette, France). Both systems have been validated
by others (Garcia et al., 1985; Goussard et al., 1991) and
used for pS2 and total cathepsin D assay by many research
groups (Spyratos et al., 1989; Brouillet et al., 1990; Goussard
et al., 1991; Marsigliante et al., 1992).
Receptor assays
For routine steroid-binding assays of ER and PR with the
dextran-coated charcoal (DCC) method, procedures were
used exactly as recommended by the EORTC Breast Cancer
Cooperative Group (1980). Values between 3 and 20 fmol
mg-' protein have commonly been used as a cut-off point for
classifying a receptor as positive or negative. A value of
10fmolmg-' protein is used in the majority of studies (Parl
et al., 1984; Alanko et al., 1985) and in the present one.
Protein estimation
Protein estimation was carried out using the method of Brad-
ford (1976) using bovine serum albumin (BSA) as the stan-
dard.
Results
Data obtained by both centres were not significantly different
as assessed by using the non-parametric Mann-Whitney-
Wilcoxon's rank-sum test (MWW) (P>0.5); data were
therefore combined to gain a single population for further
analyses.
Steroid receptor status
A total of 176 tumours (66.2%) were ER positive, with
concentration ranging from 10 to 642 (mean ± s.d. 70 ± 102,
median 34) fmol mg-' protein. Of the 266 tumours, 162 were
PR positive (60.9%), with concentration ranging from 10 to
760 fmol mg-' protein (mean ± s.d. 74.6 + 128, median 14.5).
Spearman's rank correlation between ER and PR was
rs= 0.41 (P<0.0001). No significant differences in the ex-
pression of ER and PR taken from N+ and N- patients
were found (MWW: P>0.2).
pS2 expression
pS2 content ranged from 0 to 182 ng mg-' protein (mean±
s.d. 21.2 ± 2, median 5.0).
pS2 concentration did not vary significantly between
lymph node-positive and -negative patients (MWW: P>0.5).
There were no significant differences in pS2 expression by
stratifying tumours on the basis of their size (T) by using
Kruskal-Wallis one-way analysis (P = 0.33).
Associations between pS2 andsteroid receptor status
Tumours expressing ER had higher levels of pS2 than those
which did not (MWW: P = 3 x 10-10) (Figure 1). pS2 was
also quantitatively associated with the expression of ER and
PR, in that rank correlation by Spearman's gave rs = 0.38,
P<0.0001, and rs = 0.29, P = 0.022, respectively.
pS2 values in tumours coexpressing both receptors (ER+/
PR+, n = 126) were significantly higher than those found in
either the remaining ones (n = 140) (MWW: P = 2 x 10-10)
(Figure 1) and in the ER-/PR- tumours (n = 54) (MWW:
P = 4 x 10-'°) (Figure 2). No differences in pS2 expression
between ER+/PR+ and either ER+/PR- (MWW: P =
0.13) and ER-/PR+ (MWW: P = 0.17) were found (Figure
2). Conversely, pS2 expression in the ER-/PR- group was
statistically different from both ER+/PR- (MWW: P=
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Figure 1 Box and whiskers representation of pS2 concentration
values stratified in the groups of tumours having different steroid
receptor status. P-values obtained by Mann-Whitney-Wilcoxon's
test. In this representation, the central box covers the middle
50% of the data values, between the upper and lower quartiles.
The bars extend out to the extremes, while the central line is at
the median. Those values which are beyond 1.5 times the inter-
quartile range beyond the central box are plotted as individual
points.
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Figure 2 Cumulative distribution function plots of pS2 concen-
trations, in ER+/PR+, ER-/PR+, ER+/PR-, and ER-/
PR- tumours. P-values obtained by Mann-Whitney-Wilcoxon's
test.
0.0001) and ER-/PR+ (MWW: P=7xlO-i) groups
(Figure 2).
Total cathepsin D distribution
All 266 tumours were cathepsin D positive (cathepsin D
concentration > 5 pmol mg-' protein was considered the
lower limit of detection for the assay, i.e. value significantly
different from zero). Cathepsin D values ranged from 5 to
194, with a mean value of 60 pmol mg' protein (median
51.0) (Figure 3).
Correlation between ER or PR and cathepsin D concentra-
tion was not significant by Spearman's rank correlation
(P = 0.14 for ER and P = 0.29 for PR). ER-positive tumours
did not have higher cathepsin D levels than ER-negative
samples (MWW: P = 0.24). Cathepsin D was associated with
the coexpression of ER and PR, but this finding did not
reach significance (MWW: P = 0.08). However, tumours co-
expressing ER, PR and high levels of pS2 (ER+/PR+/
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the N- subgroup Spearman's correlation gave rs = 0.14
(P>0.05), in the N+ subgroup rs was 0.32 (P<0.0001)
(Figure 4).
pS2 and cathepsin D status in the ER+/PR- and
ER-/PR+ groups
With regard to menopausal status, the ER+/PR+ group
significantly differed from the ER- /PR+ group (Fisher's
exact test: P = 0.00045) but not from the ER+ /PR- group
(P>0.5) (Figure 5). Statistical analysis showed that cathep-
sin D and pS2 expressions in the ER+/PR+ group were not
different from the expressions in the ER- /PR+ group
(Figure 2) (MWW: P = 0.39 and P = 0.17 respectively).
Similarly, cathepsin D and pS2 expressions in the ER-/
PR+ group were not significantly different from their expres-
sions in the ER+/PR- group (Figure 2) (MWW: P = 0.40
and P = 0.37 respectively).
PR concentration in the ER- /PR+ group was not
different from the concentration observed in the ER+/PR+
group (MWW: P = 0.28). Similarly, ER concentration in the
ER+/PR+ group was not different from ER concentration
in the ER+/PR- group by MWW (P>0.05).
Discussion
It is generally accepted that both PR and pS2 are induced by
ER in oestrogen-dependent breast cancer cells (Horwitz et
al., 1975; Horwitz & McGuire, 1978; Masiakowski et al.,
200
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Figure 3 Box and whiskers representation of cathepsin D con-
centration values in the whole group and stratified in the groups
of tumours having different steroid receptor and pS2 status.
P-values obtained by Mann-Whitney-Wilcoxon's test.
pS2High, n = 82) (PS2High = pS2 values above the median: 5 ng
mg 1) appeared to have higher levels of cathepsin D than
those which were negative for at least one protein (MWW
test: P = 2 x 10-5) and than those which expressed none of
them (ER-/PR-/pS2LO,W n = 44, MWW: P = 4 x 10-'). The
stratification of cathepsin D in some of these subgroups is
shown in Figure 3.
No significant differences in cathepsin D concentration
were found between samples taken from lymph node-positive
and lymph node-negative patients (MWW: P>0.05). Fur-
thermore, no significant differences in the expression of
cathepsin D were obtained by stratifying tumours on the
basis of their size (Kruskal-Wallis: P = 0.1).
Associations between pS2 and total cathepsin D
Tumours were divided in two subgroups of equal size
(n = 133) differing for pS2 value (pS2 above and below
the median) and a stratification of cathepsin D was there-
fore obtained; tumours expressing pS2> 5 ng mg' protein
(pS2High) had significantly higher level of cathepsin D than
tumours expressing less than 5 ngmg' protein pS2 (pS2LOW)
(MWW: P = 0.00001) (Figure 3). Multiple linear regression
analysis performed between cathepsin D (treated as the
dependent variable) and the logarithmic transformation of
the independent variables ER, PR and pS2 (the distributions
of these parameter levels were highly skewed and the quan-
titative values expressed as logarithms are nearer to nor-
mality) indicated that pS2 was the most important variable
and the better predictor in cathepsin D determination. Spear-
man's rank correlation between pS2 and cathepsin D concen-
tration values was weak (rs = 0.21) but highly significant
(P<0.0001). Non-parametric correlations were also per-
formed after dividing the patients into N+ and N-; while in
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Figure 4 Scatter plots of cathepsin D and pS2 concentration
values with linear regression on the lymph node-negative (top)
and -positive (bottom) carcinomas. In these scatter diagrams the
logarithmic transformation of pS2 is used for a better representa-
tion of its concentration values. P-values obtained by Spearman's
rank correlation.
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Figure 5 Distribution ofsteroid receptor phenotypes (in per cent) in the patients in pre- and post-menopause. In brackets is shown
the number of the patients. P-values obtained by Fisher's exact test.
1982). We confirmed a strict relationship between pS2 and
both ER and PR (Figures 1 and 2) (Rio et al., 1987; Foekens
et al., 1990; Goussard et al., 1991; Henry et al., 1991; Cap-
pelletti et al., 1992; Koerner et al., 1992; Predine et al., 1992),
and showed that pS2 values are actually higher in those
tumours having both ER and PR than in the remaining ones.
The most remarkable finding seems to be the relationship
between cathepsin D and pS2 values (Figures 3 and 4). This
is supported by the multiple linear regression indicating that
the effects of ER and PR on cathepsin D expression are quite
marginal relative to the effects provoked by the pS2 protein.
Unfortunately this attempt to disentangle and measure the
effects of ER, PR and pS2 on cathepsin D is limited by the
fact that the three independent variables are highly inter-
related. More feasible analysis can however be obtained
stratifying tumours by the pS2 median value and applying
tests for significance levels. In this way, it can be shown that
tumours having more than 5 ngmg-' protein pS2 expressed
higher levels ofcathepsin D than the tumours having pS2 less
than 5 ngmg-' protein (Figure 3). However, at least one bias
is inherent in this analysis because of the arbitrary cut-off
chosen. A further analysis independent of cut-off points also
showed interrelationship between the two variables (Figure
4). Interestingly, it can be seen that, in patients with positive
lymph nodes, a significantly higher correlation between pS2
and total cathepsin D occurred than in the N- patients
(P<0.0001 and P>0.05 respectively). This relation between
pS2 and cath*psin D could be explained by the hypothesis
that a direct control of pS2 on total cathepsin D expression
exists in breast cancer, especially in lymph node-positive
patients. This hypothesis may provide an explanation for the
observed up-regulation of both pS2 and cathepsin D in
ER-positive breast cancer cell lines following oestradiol
administration (Cavailles et al., 1989). Obviously, the major
driving force in the whole machinery would remain the oes-
trogen receptor and its functionality, a functional ER being
able to bind steroid and thereafter initiate transcription of
oestrogen-regulated proteins, including PR and pS2. At this
stage, pS2 might function as a growth factor perhaps able to
interact by paracrine mechanisms with other cells (also non-
responsive to the oestrogen) and to facilitate lymph node
metastasis through the expression of cathepsin D. The
involvement of both ER+ and ER- tumour cells by pS2
paracrine mechanisms, amplifying the oestrogen signal, may
account for the lack of correlation between cathepsin D and
ER values in breast cancer biopsies. In this study, tumours
expressing both steroid receptors and high pS2 concentra-
tions had higher cathepsin D levels (Figure 3), a status
suggestive ofintact, functional oestrogen receptor machinery.
Adjuvant hormone therapy, by antagonising oestrogen-
mediated induction of pS2, would be expected to present
cathepsin D up-regulation in such tumours.
ER has been used as a predictor ofprognosis and response
to endocrine therapy in breast cancer patients. Moreover,
determination of the PR concentration is of equal or greater
value than determination of the ER concentration for predic-
ting the disease-free survival of patients and response to
endocrine treatment (Clark et al., 1983); however, the ER+/
PR+ status appears to be the best prognostic factor for
assessing response (Fisher et al., 1983; Alanko et al., 1985;
Alexieva-Figusch et al., 1988). Conversely, pS2's role in
predicting prognosis is contradictory (Foekens et al., 1990;
Henry et al., 1991; Cappelletti et al., 1992; Predine et al.,
1992), but it seems to be associated with a response to
hormonal therapy (Schwartz et al., 1991). Clearly, the deter-
mination of the pS2 values in patients whose tumours express
only one of the two sex steroid receptors could help in the
prediction of response to hormonal therapy. We found that
36/266 (13.5%) tumours were ER-/PR+ and that 50/266
(18.8%) tumours were ER+/PR-; both groups contained
high levels of pS2, with concentration similar to those found
in the ER+/PR+ group (Figure 2). Here, the presence of
pS2 would guarantee also the presence of an ER able to
activate transcription, but such information should be also
associated with the saturation analysis of ER, if one wishes
to ascertain its ligand-dependent nature. The ER-/PR+
tumours derived mainly from premenopausal patients (Figure
5) whose tumours could well contain high circulating steroid
levels and therefore endogenous hormone-filled receptors
(Seriff & Durant, 1981), not assayable by steroid-binding
methods. Conversely, 30 out of 50 ER+/PR- patients were
post-menopausal (Figure 5). Here, one may wish to deter-
mine if such ER is non-functional (as aberrant receptor
forms exist which bind ligand but are unable to activate
transcription; Sherman et al., 1978; Rusconi & Yamamoto,
1987), or whether it is still a biologically active ligand-
dependent system which can be 'switched off by classical
anti-oestrogens such as tamoxifen. Clearly, the presence of
both PR and pS2 is a strong indicator of endocrine respon-
siveness.
In conclusion, we have shown that, in breast tumour
cytosols, a relationship between pS2 and total cathepsin D
exists which could point to a possible role of pS2 in cathep-
sin D overexpression. Also, pS2 can be conveniently used in
the determination of a functional ER.
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